Drugs / BMS-824393
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00971308 | Oct 2009 → Aug 2010 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01142700 | Jul → Dec 2010 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-10-01 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Compounds to be Presented at AASLD 2010 bms.com ↗
BMS-824393 is a Potent Hepatitis C Virus NS5A Inhibitor with Substantial Antiviral Activity When Given as Monotherapy in Subjects with Chronic Genotype 1 HCV Infection |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-10-01 | Bristol-Myers Squibb | New Data on Multiple Bristol-Myers Squibb Compounds to be Presented at AASLD 2010 bms.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-824393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01142700 ↗ |
| Route | Oral | “Capsule, Oral, 50mg, Once Daily, 3 days” NCT00971308 ↗ |